We are live on ! Find out more
OCUL icon

Ocular Therapeutix

72 hedge funds and large institutions have $128M invested in Ocular Therapeutix in 2016 Q3 according to their latest regulatory filings, with 10 funds opening new positions, 30 increasing their positions, 12 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

150% more repeat investments, than reductions

Existing positions increased: 30 | Existing positions reduced: 12

33% more capital invested

Capital invested by funds: $96.4M → $128M (+$32.1M)

17% more call options, than puts

Call options by funds: $1.29M | Put options by funds: $1.11M

0% more funds holding in top 10

Funds holding in top 10: 33 (0)

4% less funds holding

Funds holding: 7572 (-3)

23% less first-time investments, than exits

New positions opened: 10 | Existing positions closed: 13

Holders
72
Holders Change
-3
Holders Change %
-4%
% of All Funds
1.92%
Holding in Top 10
3
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.08%
New
10
Increased
30
Reduced
12
Closed
13
Calls
$1.29M
Puts
$1.11M
Net Calls
+$187K
Net Calls Change
+$20K
Name Holding Trade Value Shares
Change
Change in
Stake
Citadel Advisors
76
Citadel Advisors
Florida
-$352K -57,791 Closed
Renaissance Technologies
77
Renaissance Technologies
New York
-$234K -47,300 Closed
GGHC
78
Gilder Gagnon Howe & Co
New York
-$223K -45,150 Closed
ARTA
79
A.R.T. Advisors
New York
-$190K -38,433 Closed
V
80
Veritable
Delaware
-$149K -30,143 Closed
Millennium Management
81
Millennium Management
New York
-$144K -28,997 Closed
HCM
82
Highbridge Capital Management
New York
-$111K -22,354 Closed
Simplex Trading
83
Simplex Trading
Illinois
-$58.4K -9,574 Closed
Teacher Retirement System of Texas
84
Teacher Retirement System of Texas
Texas
-$9K -1,723 Closed
Citigroup
85
Citigroup
New York
-$8K -1,620 Closed

OCUL Hedge Fund Activity: Q3 2016 in Review

72 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Ocular Therapeutix (OCUL) for Q3 2016, worth a combined $128M — up 33% from $96.4M a quarter earlier.

Sellers outnumbered buyers: 13 funds closed out of OCUL and 10 opened new positions — a net loss of 3 holders — while 12 trimmed existing stakes and 30 added.

The largest buyer was Morgan Stanley, adding an estimated $2.89M. The largest seller was Federated Hermes, cutting an estimated $6.92M.

  • 72 institutional investors held Ocular Therapeutix (OCUL) as of Q3 2016, down from 75 in Q2 2016.
  • Funds reported $128M of Ocular Therapeutix stock for Q3 2016, up 33% quarter-over-quarter.
  • 10 funds opened new Ocular Therapeutix positions in Q3 2016 and 13 closed out, a net change of -3 holders.
  • The largest Ocular Therapeutix buyer in Q3 2016 was Morgan Stanley, an estimated $2.89M added.
  • The largest Ocular Therapeutix seller in Q3 2016 was Federated Hermes, an estimated $6.92M sold.

Based on aggregated 13F filings for Q3 2016.